Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Clinical Studies
  • View item
  • Home
  • ICR Divisions
  • Clinical Studies
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.

Thumbnail
View/Open
Accepted version (344.4Kb)
Date
2016-06
ICR Author
Larkin, James
Author
Spain, L
Larkin, J
Type
Journal Article
Metadata
Show full item record
URI
https://repository.icr.ac.uk/handle/internal/574
DOI
https://doi.org/10.2217/imt.16.6
Collections
  • Clinical Studies
Subject
Humans
Melanoma
Antibodies, Monoclonal
Treatment Outcome
Immunotherapy
Survival Analysis
Clinical Trials as Topic
CTLA-4 Antigen
Antibodies, Monoclonal, Humanized
Programmed Cell Death 1 Receptor
Drug-Related Side Effects and Adverse Reactions
Ipilimumab
B7-H1 Antigen
Nivolumab
Research team
Melanoma and Kidney Cancer
Language
eng
License start date
2016-06
Citation
Immunotherapy, 2016, 8 (6), pp. 677 - 679

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.